The collaboration aims at using real-world data collected from scientific publications and other open sources to provide insights into the latest infectious disease outbreaks. Using Lifebit's real-world evidence analysis system, REAL platform, will help Boehringer Ingelheim prioritize its research and development efforts.

As part of the partnership, researchers from both organizations will work together to combine real-world evidence and AI algorithms to identify infectious disease outbreaks and respond accordingly. Lifebit will use REAL's advanced analytic capabilities to automatically notify users of relevant outbreaks, such as transboundary disease spread or the emergence of novel pathogens like COVID-19. The system is built on an active learning architecture, meaning that as more relevant data are ingested, the accuracy of the system will increase.

Financial details of the partnership were not disclosed.